John Rim

John Rim serves as CEO of Samsung Biologics, the world's largest biopharmaceutical contract development and manufacturing organization (CDMO). Operating four massive production plants in Incheon, South Korea, Samsung Biologics has over 604,000 liters of total bioreactor capacity — more than any other single-site CDMO operation globally. The company manufactures monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and other complex biologics for global pharmaceutical clients. Samsung Biologics has grown explosively since its founding in 2011, leveraging Samsung Group's manufacturing expertise to build state-of-the-art facilities at unprecedented speed and scale. Plant 1 (30,000L) opened in 2013, Plant 2 (152,000L) in 2016, Plant 3 (180,000L) in 2018, and Plant 4 (240,000L+) is the newest addition. The company is also constructing additional capacity to meet surging demand. The biopharmaceutical CDMO industry is experiencing a structural boom: the global biologics pipeline is expanding rapidly, pharma companies increasingly outsource manufacturing to specialists rather than building their own facilities, and the complexity of next-generation biologics (bispecifics, ADCs, cell and gene therapies) favors experienced manufacturers. Key stock drivers include new contract wins, plant utilization rates, capacity expansion, biologics pipeline growth, pricing trends, competitive dynamics with Lonza, WuXi Biologics, and Boehringer Ingelheim Biopharmaceuticals, and the Samsung Bioepis biosimilar business performance.